Cargando…

The taxonomy of subjective cognitive decline: proposal and first clinical evidence from the Geneva memory clinic cohort

BACKGROUND: Subjective Cognitive Decline (SCD) is characterized by subjective cognitive complaints without objective cognitive impairment and is considered a risk factor for cognitive decline and dementia. However, most SCD patients will not develop neurodegenerative disorders, yet they may suffer f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ribaldi, Federica, Palomo, Rafael, Altomare, Daniele, Scheffler, Max, Assal, Frederic, Ashton, Nicholas J., Zetterberg, Henrik, Blennow, Kaj, Abramowicz, Marc, Garibotto, Valentina, Chicherio, Christian, Frisoni, Giovanni B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Journal Experts 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949231/ https://www.ncbi.nlm.nih.gov/pubmed/36824709 http://dx.doi.org/10.21203/rs.3.rs-2570068/v1

Ejemplares similares

Prognostic value of imaging-based ATN profiles in a memory clinic cohort
por: Peretti, Débora E., et al.
Publicado: (2023)

Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design
por: Ribaldi, Federica, et al.
Publicado: (2021)

Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic
por: Altomare, Daniele, et al.
Publicado: (2023)

Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison
por: Altomare, Daniele, et al.
Publicado: (2021)

The Clinical Use of Alzheimer’s Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer’s Disease Consortium Survey
por: Caprioglio, Camilla, et al.
Publicado: (2022)

Unsupervised [(18)F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer’s disease
por: Quattrini, Giulia, et al.
Publicado: (2023)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

The Biological Substrate of the Motoric Cognitive Risk Syndrome: A Pilot Study Using Amyloid-/Tau-PET and MR Imaging
por: Bommarito, Giulia, et al.
Publicado: (2022)

ATN profile classification across two independent prospective cohorts
por: Peretti, Débora E., et al.
Publicado: (2023)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
por: Ashton, Nicholas J., et al.
Publicado: (2019)

Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre‐analytical conditions
por: Simrén, Joel, et al.
Publicado: (2021)

Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline
por: Lantero Rodriguez, Juan, et al.
Publicado: (2020)

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples
por: Skillbäck, Tobias, et al.
Publicado: (2013)

Sex influences clinical phenotype in frontotemporal dementia
por: Pengo, Marta, et al.
Publicado: (2022)

Editorial: Blood Biomarkers of Neurodegenerative Diseases
por: Karikari, Thomas K., et al.
Publicado: (2022)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2023)

Blood Biomarkers for Alzheimer’s Disease in Down Syndrome
por: Montoliu-Gaya, Laia, et al.
Publicado: (2021)

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Leuzy, A., et al.
Publicado: (2021)

Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease
por: Dansson, Hákon Valur, et al.
Publicado: (2021)

Prodromal frontotemporal dementia: clinical features and predictors of progression
por: Benussi, Alberto, et al.
Publicado: (2021)

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
por: Cicognola, Claudia, et al.
Publicado: (2021)

Elevated plasma neurofilament light in aging reflects brain white‐matter alterations but does not predict cognitive decline or Alzheimer's disease
por: Nyberg, Lars, et al.
Publicado: (2020)

Societal and equity challenges for Brain Health Services. A user manual for Brain Health Services—part 6 of 6
por: Milne, Richard, et al.
Publicado: (2021)

Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study
por: Rosenstein, Igal, et al.
Publicado: (2021)

Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population
por: Gleerup, Helena Sophia, et al.
Publicado: (2021)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
por: Mattsson, Niklas, et al.
Publicado: (2010)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease
por: Andreasen, Niels, et al.
Publicado: (2010)

Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders
por: Andreasson, Ulf, et al.
Publicado: (2016)

Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic
por: Bucci, Marco, et al.
Publicado: (2023)

Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
por: Raket, Lars Lau, et al.
Publicado: (2020)

Biomarkers for tau pathology
por: Schöll, Michael, et al.
Publicado: (2019)

Fluid Biomarkers for Synaptic Dysfunction and Loss
por: Camporesi, Elena, et al.
Publicado: (2020)

Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: a population-based study
por: Bäckström, David, et al.
Publicado: (2022)

Slowing gait speed precedes cognitive decline by several years
por: Skillbäck, Tobias, et al.
Publicado: (2022)

Association of plasma P-tau181 with memory decline in non-demented adults
por: Therriault, Joseph, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h6urgoucb2jsjqn2o1b9m62g78